First-Line Atezolizumab Monotherapy In Older Adults With Non-Small-Cell Lung Cancer
In a phase 3 trial of patients with advanced or metastatic non-small-cell lung cancer (NSCLC), atezolizumab monotherapy produced improved overall survival, twice the 2-year survival